Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.42 |
| ▸ | HTR1A | P08908 | 2/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | DRD1 | P21728 | 1/20 | 0.42 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.42 |
| ▸ | DRD3 | P35462 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.38 |
| ▸ | ADRB2 | P07550 | 5/20 | 0.38 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22481126 | 0.86 | CYP2D6 (0.43) | CYP2D6CYP2C9HTR1ASLC6A2SLC6A4 | |
| SCHEMBL22481131 | 0.86 | ADRB2 (0.47) | CYP2D6CYP2C9HTR1ASLC6A2SLC6A4 | |
| SCHEMBL22481304 | 0.82 | CYP2D6 (0.40) | CYP2D6CYP2C9HTR1ASLC6A2SLC6A4 | |
| SCHEMBL22481336 | 0.78 | ADRB2 (0.44) | CYP2D6CYP2C9HTR1ASLC6A2SLC6A4 | |
| SCHEMBL22480686 | 0.78 | CYP2D6 (0.49) | CYP2D6CYP2C9HTR1ASLC6A2SLC6A4 | |
| SCHEMBL22481297 | 0.75 | ADRB2 (0.48) | CYP2D6CYP2C9HTR1ASLC6A2SLC6A4 | |
| SCHEMBL22481222 | 0.73 | ADRB2 (0.36) | CYP2D6CYP2C9HTR1ASLC6A2SLC6A4 | |
| SCHEMBL22480716 | 0.72 | CYP2D6 (0.44) | CYP2D6CYP2C9HTR1ASLC6A2SLC6A4 | |
| SCHEMBL22481009 | 0.72 | ADRB2 (0.50) | CYP2D6CYP2C9HTR1ASLC6A2SLC6A4 | |
| SCHEMBL9641337 | 0.67 | ADRB2 (0.54) | CYP2D6CYP2C9HTR1ASLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230263749-A1 | COMPOSITIONS AND METHODS FOR IMPROVING NEUROLOGICAL DISEASES AND DISORDERS | CURASEN THERAPEUTICS, INC. | 2023-08-24 | — | — | US | disclosed |
| US-20230263749-A1 | COMPOSITIONS AND METHODS FOR IMPROVING NEUROLOGICAL DISEASES AND DISORDERS | CURASEN THERAPEUTICS, INC. | 2023-08-24 | — | — | US | disclosed |
| US-20230157974-A1 | COMPOSITIONS AND METHODS FOR IMPROVING NEUROLOGICAL DISEASES AND DISORDERS | CURASEN THERAPEUTICS, INC. | 2023-05-25 | — | — | US | disclosed |
| US-20220169612-A1 | BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAME | CURASEN THERAPEUTICS, INC. | 2022-06-02 | — | — | US | disclosed |
| US-20210371380-A1 | BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAME | CURASEN THERAPEUTICS, INC. | 2021-12-02 | — | — | US | disclosed |
| US-11040944-B2 | Beta adrenergic agonist and methods of using the same | CURASEN THERAPEUTICS, INC. (US) | 2021-06-22 | — | — | US | disclosed |
| US-10947196-B2 | Beta adrenergic agonist and methods of using the same | CURASEN THERAPEUTICS, INC. (US) | 2021-03-16 | — | — | US | disclosed |
| US-20200308115-A1 | BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAME | CURASEN THERAPEUTICS, INC. | 2020-10-01 | — | — | US | disclosed |
| US-20200308114-A1 | BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAME | CURASEN THERAPEUTICS, INC. | 2020-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200308114-A1 | BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAME | ADRB2, ADRB1, ADRA2C | CYP2D6 946/4885CYP2C9 2374/4885HTR1A 154/4885 |
| US-20200308115-A1 | BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAME | ADRB2, ADRB1, ADRA2C | CYP2D6 946/4885CYP2C9 2374/4885HTR1A 154/4885 |
| US-10947196-B2 | Beta adrenergic agonist and methods of using the same | ADRB2, ADRB1, ADRA2C | CYP2D6 946/4885CYP2C9 2374/4885HTR1A 154/4885 |
| US-20210371380-A1 | BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAME | ADRB2, ADRB1, ADRA2C | CYP2D6 946/4885CYP2C9 2374/4885HTR1A 154/4885 |
| US-11040944-B2 | Beta adrenergic agonist and methods of using the same | ADRB2, ADRB1, ADRA2C | CYP2D6 946/4885CYP2C9 2374/4885HTR1A 154/4885 |
| US-20220169612-A1 | BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAME | ADRA2B, ADRB2, ADRB1 | CYP2D6 866/4885CYP2C9 2134/4885HTR1A 147/4885 |
| US-20230263749-A1 | COMPOSITIONS AND METHODS FOR IMPROVING NEUROLOGICAL DISEASES AND DISORDERS | ADRA2A, SNCA, ADRA1A | CYP2D6 3407/4885CYP2C9 4500/4885HTR1A 50/4885 |
| US-20230157974-A1 | COMPOSITIONS AND METHODS FOR IMPROVING NEUROLOGICAL DISEASES AND DISORDERS | ADRA2A, SNCA, ADRA1A | CYP2D6 3407/4885CYP2C9 4500/4885HTR1A 50/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.